1. Home
  2. FHN vs TGTX Comparison

FHN vs TGTX Comparison

Compare FHN & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Horizon Corporation

FHN

First Horizon Corporation

HOLD

Current Price

$24.59

Market Cap

11.0B

Sector

Finance

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$30.80

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FHN
TGTX
Founded
1864
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.0B
5.5B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
FHN
TGTX
Price
$24.59
$30.80
Analyst Decision
Buy
Strong Buy
Analyst Count
18
4
Target Price
$24.61
$54.75
AVG Volume (30 Days)
5.5M
1.4M
Earning Date
01-15-2026
11-03-2025
Dividend Yield
2.45%
N/A
EPS Growth
20.88
N/A
EPS
1.65
2.78
Revenue
$3,184,000,000.00
$531,898,000.00
Revenue This Year
$10.95
$87.88
Revenue Next Year
$2.82
$48.75
P/E Ratio
$14.81
$11.19
Revenue Growth
3.68
100.88
52 Week Low
$15.19
$25.28
52 Week High
$24.75
$46.48

Technical Indicators

Market Signals
Indicator
FHN
TGTX
Relative Strength Index (RSI) 72.25 46.61
Support Level $23.54 $29.79
Resistance Level $24.75 $31.37
Average True Range (ATR) 0.43 1.03
MACD 0.09 0.03
Stochastic Oscillator 88.68 49.61

Price Performance

Historical Comparison
FHN
TGTX

About FHN First Horizon Corporation

First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: